403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
AIM Vaccine Has Obtained Clinical Approval For Two Heavyweight Products, Creating New Growth Points For Performance
(MENAFN- The Arabian Post) HONG KONG SAR – Media OutReach Newswire – 20 December 2024 – AIM Vaccine (06660) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and second generation of highly-effective absorbed tetanus vaccine have been recently obtained from [...]">
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment